跳至主要内容
临床试验/NCT06293612
NCT06293612已完成不适用

Role of Microenvironment Analysis and MRI Radiomic Study in the Risk Stratification of Distant Metastases in Rectal Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences1 个研究点 分布在 1 个国家目标入组 302 人开始时间: 2015年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
302
试验地点
1
主要终点
Heterochronous distant metastasis

研究概览

简要总结

The goal of this observational study is to construct a multimodal intelligent model to predict the risk of heterochronous metastasis of rectal cancer, which is helpful for individualized diagnosis and treatment and follow-up planning. The main questions it aims to answer are:

  • what are the independent risk factors of distant metastasis (DM) in locally advanced rectal cancer (LARC)
  • What is the influence weight of the above factors on the heterochronous metastasis of LARC, and how to build a risk-prediction model

This study will not affect or interfere with the routine medical diagnosis and treatment of participants, and will not increase the cost and risk of participants. Participant's information is protected and identified by a unique code.

详细描述

Data collection process in strict implementation of special management, the full name of quality control. Special personnel are responsible for collecting clinical images and pathological information of patients in the medical record system, and personal identification data will be used to identify and process, in order to protect the privacy of test patients/participants. At the same time, there is a special person responsible for quality control and source data verification. Participants use the project unified number as the unique identification code, personal data and case information by the sample management personnel input and save, the user only see the individual number, no longer show the participants' name and other personal information. Data dictionary that contains detailed descriptions of each variable used by the registry, including the source of the variable, coding information was built. Participants' sample information is stored electronically in a dedicated computer that is not used for other purposes and is provided with a password, which is only available to the person (1 person) who manages the sample. Participants' medical records will be kept at the hospital and will be accessible only to researchers; If necessary, members of the bidding organization, ethics committee or government management department may access the personal data of the participants according to the corresponding authority. The results of the study will be published as statistically analyzed data and will not contain any identifiable participant information.

The sponsor is responsible for implementing and maintaining quality assurance and quality control systems with written Standard Operating Procedures (SOPs) to ensure that trials are conducted and data are generated, documented (recorded), and reported in compliance with the protocol, good clinical practices (GCP), and the applicable regulatory requirement(s). The SOPs should cover system setup, installation, and use. The SOPs should describe system validation and functionality testing, data collection and handling, system maintenance, system security measures, change control,data backup, recovery, contingency planning, and decommissioning. The responsibilities of the sponsor, investigator, and other parties with respect to the use of these computerized systems should be clear, and the users should be provided with training in use. Noncompliance with the protocol,SOPs,GCP, and/or applicable regulatory requirement(s) by an investigator/institution, or by member(s) of the sponsor's staff should lead to prompt action by the sponsor to secure compliance.

According to the morbidity of LARC and the risk of distant metastasis, the sample size is 300, and the follow-up interval is at least 3 years.

Plan for missing data: If the proportion of missing data is very large, such as greater than 95%, the investigators can directly remove this field; At 50~95%, the investigators have two processing methods, one is to remove this field directly; another way is to turn the field into an indicator variable; that is the 0-1 variable. If the field is empty, the field is 0; Otherwise the field is 1. Between 5% and 50% : In this scenario, the investigators need to fill in the missing values. In the process of filling, there are two categories: simple filling and algorithm filling. Simple filling includes: 0 filling, mean filling, median filling, mode filling; Algorithm filling methods such as K Nearest Neighbors (KNN) filling, random forest filling and so on.

Statistics Statistical Product and Service Solutions (SPSS, version 26.0) and R software (version 4.0.5) were used for statistical analyses. Receiver operating characteristic (ROC) curve analysis was used to evaluate the optimum cutoff value of tumor stromal ratio (TSR) in discriminating DM risk based on the maximum Youden index. Heat maps showed the distribution of variables between patients with or without DM within 3 years. The independent DMFS risk factors were determined using Kaplan-Meier (K-M) curves and Cox regression analysis sequentially based on the data of the training cohort. Statistical significance was set at P<0.05. Inter-observer variability was assessed using κ statistics for categorical and ranked variables, and ICC for continuous variables.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Newly diagnosed non-mucinous LARC (T3~T4, or any T with N1~2, M0) without previous treatment;
  • No concomitant malignancies or systemic disease;
  • Complete standard neoadjuvant chemoradiotherapy (NCRT) and radical surgery in our institute;
  • Underwent rectal MRI and colonoscopy within 2 weeks before NCRT.

排除标准

  • Fail to meet any of the inclusion criteria;
  • Inadequate MR image quality for analysis, or lack of biopsy tissue for TSR assessment;
  • Incomplete clinical data or withdraw before last visit.
  • A total of 578 eligible LARC cases were initially reviewed, 276 of which were excluded according to the exclusion criteria. Finally, 302 patients were enrolled in this study and randomized into a training cohort (n = 211) and validation cohort (n = 91).

结局指标

主要结局

Heterochronous distant metastasis

时间窗: Through study completion, an average of 3 years

Defined as cancer recurrence at sites outside the pelvis based on radiological and/or histopathological evidence.

次要结局

  • Distant metastasis-free survival(From the date of surgery to the date of the first detection of distant metastasis, death from any cause, assessed up to 3 years.)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Constructing a Multimodal Imaging System to Predict... | 临床试验